| Autor: |
Bobkov VA; LLC 'IBC Generium,' Volginskiy, Russia ., Tikhonov RV; LLC 'IBC Generium,' Volginskiy, Russia ., Shuster AM; LLC 'IBC Generium,' Volginskiy, Russia ., Poteryaev DA; LLC 'IBC Generium,' Volginskiy, Russia ., Bade VN; LLC 'IBC Generium,' Volginskiy, Russia . |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research [J Interferon Cytokine Res] 2017 Jul; Vol. 37 (7), pp. 325-329. Date of Electronic Publication: 2017 Jun 01. |
| DOI: |
10.1089/jir.2016.0114 |
| Abstrakt: |
C1 esterase inhibitor (C1INH) is an abundant component of blood plasma (the average concentration is 250 mg/L); it is known to be involved in several biological processes, for instance, in the regulation of the coagulation system, adhesion of leukocytes on endothelial cells, and in the regulation of complement and kallikrein cascades. Lately, the role of C1INH in immunomodulation has gained considerable attention. We used an ex vivo whole blood model to examine the influence of C1INH and its mutated variants on the inflammatory cytokines interleukin (IL)-6, tumor necrosis factor-α (TNFα), and IL-1β. The present study demonstrated for the first time that recombinant C1INH or its Seprin domain can downregulate bacterial endotoxin induced IL-6 release. We also observed that unstructured N-terminal domain of C1INH downregulates the release of IL-1β and TNFα, but not IL-6. Our results suggest that C1INH may have therapeutic potential for treatment of inflammatory conditions. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
